Huntington’s Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

September 24 04:02 2023
Huntington's Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

DelveInsight’s, “Huntington’s Disease Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the Huntington’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Huntington’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Huntington’s Disease Pipeline Report

  • DelveInsight’s Huntington’s Disease pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Huntington’s Disease treatment.
  • The leading companies working in the Huntington’s Disease Market include Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others.
  • Promising Huntington’s disease Pipeline therapies in the various stages of development include Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.
  • September 2023: ExoRNA Bioscience announced a study of early phase 1 clinical trials for ER2001 injection. This is an open label, dose escalation clinic trial of ER2001 intravenous injection to evaluate safety, tolerability and pharmacokinetics of ascending single and multiple doses of intravenously administered ER2001 in patients with early manifest Huntington’s Disease.
  • September 2023: PTC Therapeutics announced a study of phase 2 clinical trials for  PTC518. The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

 

Request a sample and discover the recent advances in Huntington’s Disease Treatment Drugs @ Huntington’s Disease Pipeline Report

 

In the Huntington’s Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Huntington’s Disease Overview

Huntington’s disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. It is an autosomal dominant disorder caused by a single defective gene on chromosome 4. The symptoms of Huntington’s Disease include involuntary jerking or writhing movements (chorea), muscle problems, such as rigidity or muscle contracture (dystonia), slow or abnormal eye movements, impaired balance, difficulty with speech or swallowing, difficulty organizing, prioritizing or focusing on tasks, and/or fatigue and loss of energy.

 

Find out more about Huntington’s Disease Treatment Drugs @ Drugs for Huntington’s Disease Treatment

 

Huntington’s Disease Emerging Drugs Profile

  • Pridopidine: Prilenia Therapeutics
  • Tominersen: Ionis Pharmaceuticals

 

Huntington’s Disease Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Huntington’s Disease therapies. The Huntington’s Disease companies which have their Huntington’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

 

Learn more about the emerging Huntington’s Disease Pipeline Therapies @ Huntington’s Disease Clinical Trials Assessment

 

Scope of the Huntington’s Disease Pipeline Report

  • Coverage- Global
  • Huntington’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Huntington’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Huntington’s Disease Companies- Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others.
  • Huntington’s disease Pipeline therapies- Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.

 

Dive deep into rich insights for new drugs for Huntington’s Disease treatment, Visit @ Huntington’s Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Huntington’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Huntington’s Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pridopidine: Prilenia Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical/Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Huntington’s Disease Key Companies
  21. Huntington’s Disease Key Products
  22. Huntington’s Disease- Unmet Needs
  23. Huntington’s Disease- Market Drivers and Barriers
  24. Huntington’s Disease- Future Perspectives and Conclusion
  25. Huntington’s Disease Analyst Views
  26. Appendix

 

For further information on the Huntington’s Disease pipeline therapeutics, reach out to Huntington’s Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

  Categories: